Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 4, Issue 12, Pages 988-1004Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd1902
Keywords
-
Ask authors/readers for more resources
Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available